Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial.
Oleg Gluz
Honoraria - Amgen
Hans Heinrich Kreipe
No relevant relationships to disclose
Matthias Christgen
No relevant relationships to disclose
Tom Degenhardt
No relevant relationships to disclose
Ronald E. Kates
No relevant relationships to disclose
Cornelia Liedtke
Honoraria - Sanofi
Steven Shak
Employment or Leadership Position - Genomic Health
Michael R. Clemens
Honoraria - Amgen
Marwa Salem
No relevant relationships to disclose
Susanne Markmann
No relevant relationships to disclose
Bernd Liedtke
No relevant relationships to disclose
Bahriye Aktas
No relevant relationships to disclose
Stephan Henschen
No relevant relationships to disclose
Anke Pollmanns
No relevant relationships to disclose
Petra Krabisch
No relevant relationships to disclose
Christoph Uleer
No relevant relationships to disclose
Doris Augustin
No relevant relationships to disclose
Christoph Thomssen
Honoraria - Amgen; Sanofi
Research Funding - Sanofi
Ulrike Nitz
Consultant or Advisory Role - Amgen
Honoraria - Amgen; Genomic Health; Sanofi
Research Funding - Amgen; Sanofi
Nadia Harbeck
Consultant or Advisory Role - Genomic Health; Sanofi
Honoraria - Genomic Health; Sanofi